BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36230522)

  • 21. The prognostic value of preoperative serum lactate dehydrogenase levels in patients underwent curative-intent hepatectomy for colorectal liver metastases: A two-center cohort study.
    Bai L; Lin ZY; Lu YX; Chen Q; Zhou H; Meng Q; Lin CP; Huang WL; Wan YL; Pan ZZ; Wang DS
    Cancer Med; 2021 Nov; 10(22):8005-8019. PubMed ID: 34636145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.
    Gagnière J; Dupré A; Gholami SS; Pezet D; Boerner T; Gönen M; Kingham TP; Allen PJ; Balachandran VP; De Matteo RP; Drebin JA; Yaeger R; Kemeny NE; Jarnagin WR; D'Angelica MI
    Ann Surg; 2020 Jan; 271(1):147-154. PubMed ID: 29995686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic circulating proteomic biomarkers in colorectal liver metastases.
    Kim D; Gupta B; Wong GYM
    Comput Struct Biotechnol J; 2023; 21():2129-2136. PubMed ID: 36992914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer.
    McAuliffe JC; Qadan M; D'Angelica MI
    J Gastrointest Oncol; 2015 Dec; 6(6):699-708. PubMed ID: 26697204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.
    Zarour LR; Anand S; Billingsley KG; Bisson WH; Cercek A; Clarke MF; Coussens LM; Gast CE; Geltzeiler CB; Hansen L; Kelley KA; Lopez CD; Rana SR; Ruhl R; Tsikitis VL; Vaccaro GM; Wong MH; Mayo SC
    Cell Mol Gastroenterol Hepatol; 2017 Mar; 3(2):163-173. PubMed ID: 28275683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.
    Bolhuis K; van 't Erve I; Mijnals C; Delis-Van Diemen PM; Huiskens J; Komurcu A; Lopez-Yurda M; van den Broek D; Swijnenburg RJ; Meijer GA; Punt CJA; Fijneman RJA
    EBioMedicine; 2021 Aug; 70():103498. PubMed ID: 34333237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
    Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
    J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
    BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Surgical Management Strategies for Colorectal Cancer Liver Metastases.
    Ivey GD; Johnston FM; Azad NS; Christenson ES; Lafaro KJ; Shubert CR
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.
    Boilève A; Maillard A; Wagner M; Dromain C; Laurent C; Dupont Bierre E; Le Sourd S; Audemar F; Ulusakarya A; Guerin-Meyer V; Smisth D; Pezzella V; De Baere T; Goere D; Gelli M; Taieb J; Boige V
    BMC Cancer; 2020 Jan; 20(1):74. PubMed ID: 32000724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases.
    Saied A; Katz SC; Espat NJ
    Hepatobiliary Surg Nutr; 2013 Apr; 2(2):97-107. PubMed ID: 24570923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis.
    Gau L; Ribeiro M; Pereira B; Poirot K; Dupré A; Pezet D; Gagnière J
    Eur J Surg Oncol; 2021 Nov; 47(11):2722-2733. PubMed ID: 34099355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing liver resections and pushing the envelope with resections for hepatic colorectal metastases.
    Guye ML; Schoellhammer HF; Chiu LW; Kim J; Lai LL; Singh G
    Indian J Surg Oncol; 2013 Dec; 4(4):349-55. PubMed ID: 24426756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival.
    Beppu T; Miyamoto Y; Sakamoto Y; Imai K; Nitta H; Hayashi H; Chikamoto A; Watanabe M; Ishiko T; Baba H
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S405-13. PubMed ID: 24570379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parenchymal-sparing hepatectomy for colorectal liver metastases reduces postoperative morbidity while maintaining equivalent oncologic outcomes compared to non-parenchymal-sparing resection.
    Andreou A; Gloor S; Inglin J; Di Pietro Martinelli C; Banz V; Lachenmayer A; Kim-Fuchs C; Candinas D; Beldi G
    Surg Oncol; 2021 Sep; 38():101631. PubMed ID: 34298267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases.
    Nishioka Y; Chun YS; Overman MJ; Cao HST; Tzeng CD; Mason MC; Kopetz SW; Bauer TW; Vauthey JN; Newhook TE;
    J Am Coll Surg; 2022 Apr; 234(4):474-483. PubMed ID: 35290266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis.
    Margonis GA; Buettner S; Andreatos N; Wagner D; Sasaki K; Galjart B; Kamphues C; Pawlik TM; Poultsides G; Kaczirek K; Lønning PE; Verhoef C; Kreis ME; Wolfgang CL; Weiss MJ
    J Surg Oncol; 2018 Dec; 118(7):1074-1080. PubMed ID: 30261094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced image analytics predicting clinical outcomes in patients with colorectal liver metastases: A systematic review of the literature.
    Wesdorp NJ; van Goor VJ; Kemna R; Jansma EP; van Waesberghe JHTM; Swijnenburg RJ; Punt CJA; Huiskens J; Kazemier G
    Surg Oncol; 2021 Sep; 38():101578. PubMed ID: 33866191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
    Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
    Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.